Insider · CIK 0001256088
Georges Gemayel
Files at SUPN (SUPERNUS PHARMACEUTICALS, INC.), IRON (Disc Medicine, Inc.). First filing Nov 8, 2024, latest Mar 9, 2026.
In brief
Georges Gemayel files SEC Form 4 as director at SUPN (SUPERNUS PHARMACEUTICALS, INC.), and also at IRON (Disc Medicine, Inc.). Since Nov 8, 2024, Georges Gemayel has reported 0 open-market buys worth $0 and 3 open-market sells worth $1.9M, the latest filed on Mar 9, 2026.
A track record needs three past buys with six months of prices behind them; Georges Gemayel has 0, so none is measured yet.
The newest scored trade: sold $1.0M of SUPN on Mar 5, 2026, filed Mar 9, 2026, scored 50 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $1.0M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SUPN: SUPERNUS PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | SUPERNUS PHARMACEUTICALS, INC. | $1.0M 18,787 shares | -49% | +79% from low-5% from high | |
| 41Moderate | SUPERNUS PHARMACEUTICALS, INC. | $392k 10,787 shares | -45% | - | |
| 53Moderate | SUPERNUS PHARMACEUTICALS, INC. | $520k 14,213 shares | -52% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 8,787 0.02% of outstanding | $466k | Mar 6, 2026 | $537k |
| Mar 5, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 10,000 0.02% of outstanding | $537k | Mar 5, 2026 | none |
| Nov 8, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 10,787 0.02% of outstanding | $392k | Nov 8, 2024 | $956k |
| Nov 7, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 14,213 0.03% of outstanding | $521k | Nov 7, 2024 | $435k |
Transactions
Every row this insider has filed, 23 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | IRON Disc Medicine, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +6,212 | $0.00 | $0 | 6,212 | Jun 23, 2026 |
| Mar 5, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock | -10,000 | $53.71 | $537k | 28,159 | Mar 9, 2026 |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +7,905 | $25.30 | $200k | 36,064 | Mar 9, 2026 |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock | -8,787 | $53.00 | $466k | 27,277 | Mar 9, 2026 |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Director Stock Option (Right to Buy)derivative | -7,905 | $0.00 | $0 | 0 | Mar 9, 2026 |
| Feb 23, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +15,000 | $12.98 | $195k | 33,684 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +4,475 | $0.00 | $0 | 38,159 | Feb 25, 2026 |
| Feb 23, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Director Stock Option (Right to Buy)derivative | -15,000 | $0.00 | $0 | 0 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -4,475 | $0.00 | $0 | 0 | Feb 25, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +2,989 | $0.00 | $0 | 2,989 | Feb 20, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Director Stock Option (Right to Buy)derivative | +4,977 | $0.00 | $0 | 4,977 | Feb 20, 2026 |
| Sep 16, 2025 | IRON Disc Medicine, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,000 | $0.00 | $0 | 1,000 | Sep 18, 2025 |
| Jun 11, 2025 | IRON Disc Medicine, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jun 13, 2025 |
| Feb 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +5,369 | $0.00 | $0 | 18,684 | Feb 24, 2025 |
| Feb 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitsderivative | -5,369 | $0.00 | $0 | 0 | Feb 24, 2025 |
| Feb 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Director Stock Option (Right to Buy)derivative | +7,296 | $0.00 | $0 | 7,296 | Feb 21, 2025 |
| Feb 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +4,475 | $0.00 | $0 | 4,475 | Feb 21, 2025 |
| Nov 8, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +10,787 | $11.46 | $124k | 24,102 | Nov 12, 2024 |
| Nov 8, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock | -10,787 | $36.30 | $392k | 13,315 | Nov 12, 2024 |
| Nov 8, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Director Stock Option (Right to Buy)derivative | -10,787 | $0.00 | $0 | 0 | Nov 12, 2024 |
| Nov 7, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +14,213 | $11.46 | $163k | 27,528 | Nov 8, 2024 |
| Nov 7, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock | -14,213 | $36.62 | $520k | 13,315 | Nov 8, 2024 |
| Nov 7, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Director Stock Option (Right to Buy)derivative | -14,213 | $0.00 | $0 | 10,787 | Nov 8, 2024 |
Questions about Georges Gemayel
Answered from the filings on this page, as of the latest one.
Is Georges Gemayel buying or selling?
In the last 12 months Georges Gemayel reported 0 open-market buys worth $0 and 1 open-market sell worth $1.0M on SEC Form 4; the latest was sold $1.0M of SUPN on Mar 5, 2026. Grants, option exercises and tax withholding are not counted.
How did Georges Gemayel's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Georges Gemayel has 0.
Where does Georges Gemayel file Form 4?
Georges Gemayel has filed Form 4 at SUPN (SUPERNUS PHARMACEUTICALS, INC.); IRON (Disc Medicine, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.